Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study.

<h4>Background</h4>The association between hormone treatment (HT) and mortality remains controversial. This study aimed to determine whether the risk of mortality associated with HT use varies depending on the specific characteristics of treatment and genetic variability in terms of the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joanne Ryan, Marianne Canonico, Laure Carcaillon, Isabelle Carrière, Jacqueline Scali, Jean-Francois Dartigues, Carole Dufouil, Karen Ritchie, Pierre-Yves Scarabin, Marie-Laure Ancelin
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4796f24d8e6e4869b4f36871ac089cae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4796f24d8e6e4869b4f36871ac089cae
record_format	dspace
spelling	oai:doaj.org-article:4796f24d8e6e4869b4f36871ac089cae2021-11-18T07:24:23ZHormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study.1932-620310.1371/journal.pone.0034112https://doaj.org/article/4796f24d8e6e4869b4f36871ac089cae2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22457817/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The association between hormone treatment (HT) and mortality remains controversial. This study aimed to determine whether the risk of mortality associated with HT use varies depending on the specific characteristics of treatment and genetic variability in terms of the estrogen receptor.<h4>Methodology/principal findings</h4>A prospective, population-based study of 5135 women aged 65 years and older who were recruited from three cities in France and followed over six years. Detailed information related to HT use was obtained and five estrogen receptor polymorphisms were genotyped. The total follow-up was 25,436 person-years and during this time 352 women died. Cancer (36.4%) and cardiovascular disease (19.3%) were the major causes of death. Cox proportional hazards models adjusted for age, education, centre, living situation, comorbidity, depression, physical and mental incapacities, indicated no significant association between HT and mortality, regardless of the type or duration of treatment, or the age at initiation. However, the association between HT and all-cause or cancer-related mortality varied across women, with significant interactions identified with three estrogen receptor polymorphisms (p-values = 0.004 to 0.03) in adjusted analyses. Women carrying the C allele of ESR1 rs2234693 had a decreased risk of all-cause mortality with HT (HR: 0.42, 95% CI: 0.18-0.97), while in stark contrast, those homozygous for the T allele had a significantly increased risk of cancer-related mortality (HR: 3.18, 95% CI: 1.23-8.20). The findings were similar for ESR1 rs9340799 and ESR2 rs1271572.<h4>Conclusions/significance</h4>The risk of mortality was not associated with HT duration, type or age at initiation. It was however not equal across all women, with some women appearing genetically more vulnerable to the effects of HT in terms of their estrogen receptor genotype. These findings, if confirmed in another independent study, may help explain the differential susceptibility of women to the beneficial or adverse effects of HT.Joanne RyanMarianne CanonicoLaure CarcaillonIsabelle CarrièreJacqueline ScaliJean-Francois DartiguesCarole DufouilKaren RitchiePierre-Yves ScarabinMarie-Laure AncelinPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 3, p e34112 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Joanne Ryan Marianne Canonico Laure Carcaillon Isabelle Carrière Jacqueline Scali Jean-Francois Dartigues Carole Dufouil Karen Ritchie Pierre-Yves Scarabin Marie-Laure Ancelin Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study.
description	<h4>Background</h4>The association between hormone treatment (HT) and mortality remains controversial. This study aimed to determine whether the risk of mortality associated with HT use varies depending on the specific characteristics of treatment and genetic variability in terms of the estrogen receptor.<h4>Methodology/principal findings</h4>A prospective, population-based study of 5135 women aged 65 years and older who were recruited from three cities in France and followed over six years. Detailed information related to HT use was obtained and five estrogen receptor polymorphisms were genotyped. The total follow-up was 25,436 person-years and during this time 352 women died. Cancer (36.4%) and cardiovascular disease (19.3%) were the major causes of death. Cox proportional hazards models adjusted for age, education, centre, living situation, comorbidity, depression, physical and mental incapacities, indicated no significant association between HT and mortality, regardless of the type or duration of treatment, or the age at initiation. However, the association between HT and all-cause or cancer-related mortality varied across women, with significant interactions identified with three estrogen receptor polymorphisms (p-values = 0.004 to 0.03) in adjusted analyses. Women carrying the C allele of ESR1 rs2234693 had a decreased risk of all-cause mortality with HT (HR: 0.42, 95% CI: 0.18-0.97), while in stark contrast, those homozygous for the T allele had a significantly increased risk of cancer-related mortality (HR: 3.18, 95% CI: 1.23-8.20). The findings were similar for ESR1 rs9340799 and ESR2 rs1271572.<h4>Conclusions/significance</h4>The risk of mortality was not associated with HT duration, type or age at initiation. It was however not equal across all women, with some women appearing genetically more vulnerable to the effects of HT in terms of their estrogen receptor genotype. These findings, if confirmed in another independent study, may help explain the differential susceptibility of women to the beneficial or adverse effects of HT.
format	article
author	Joanne Ryan Marianne Canonico Laure Carcaillon Isabelle Carrière Jacqueline Scali Jean-Francois Dartigues Carole Dufouil Karen Ritchie Pierre-Yves Scarabin Marie-Laure Ancelin
author_facet	Joanne Ryan Marianne Canonico Laure Carcaillon Isabelle Carrière Jacqueline Scali Jean-Francois Dartigues Carole Dufouil Karen Ritchie Pierre-Yves Scarabin Marie-Laure Ancelin
author_sort	Joanne Ryan
title	Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study.
title_short	Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study.
title_full	Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study.
title_fullStr	Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study.
title_full_unstemmed	Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study.
title_sort	hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/4796f24d8e6e4869b4f36871ac089cae
work_keys_str_mv	AT joanneryan hormonetreatmentestrogenreceptorpolymorphismsandmortalityaprospectivecohortstudy AT mariannecanonico hormonetreatmentestrogenreceptorpolymorphismsandmortalityaprospectivecohortstudy AT laurecarcaillon hormonetreatmentestrogenreceptorpolymorphismsandmortalityaprospectivecohortstudy AT isabellecarriere hormonetreatmentestrogenreceptorpolymorphismsandmortalityaprospectivecohortstudy AT jacquelinescali hormonetreatmentestrogenreceptorpolymorphismsandmortalityaprospectivecohortstudy AT jeanfrancoisdartigues hormonetreatmentestrogenreceptorpolymorphismsandmortalityaprospectivecohortstudy AT caroledufouil hormonetreatmentestrogenreceptorpolymorphismsandmortalityaprospectivecohortstudy AT karenritchie hormonetreatmentestrogenreceptorpolymorphismsandmortalityaprospectivecohortstudy AT pierreyvesscarabin hormonetreatmentestrogenreceptorpolymorphismsandmortalityaprospectivecohortstudy AT marielaureancelin hormonetreatmentestrogenreceptorpolymorphismsandmortalityaprospectivecohortstudy
_version_	1718423471339339776

Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study.

Ejemplares similares